Partnership Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.87M Sell
29,948
-1,408
-4% -$89K 1.33% 15
2026
Q2
$1.81M Buy
31,356
+770
+3% +$44.2K 1.22% 16
2026
Q1
$1.86M Sell
30,586
-8,495
-22% -$495K 1.41% 16
2025
Q4
$2.11M Buy
39,081
+1,178
+3% +$56.7K 1.52% 12
2025
Q3
$1.71M Buy
37,903
+9,155
+32% +$428K 1.32% 15
2025
Q2
$1.33M Buy
28,748
+523
+2% +$25.7K 1.08% 24
2025
Q1
$1.72M Buy
28,225
+358
+1% +$20.9K 1.46% 15
2024
Q4
$1.58M Buy
27,867
+1,658
+6% +$92.6K 1.31% 17
2024
Q3
$1.36M Sell
26,209
-10,509
-29% -$493K 0.96% 20
2024
Q2
$1.52M Sell
36,718
-9,888
-21% -$442K 1.13% 20
2024
Q1
$2.53M Buy
46,606
+27,244
+141% +$1.39M 1.77% 13
2023
Q4
$946K Buy
+19,362
New +$1.02M 0.71% 39

Other funds holding BMY

Partnership Wealth Management's BMY Position: Q3 2026 in Review

Partnership Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 4.5% in Q3 2026, selling an estimated $89K and leaving 29,948 shares worth $1.87M. The position accounts for 1.33% of the portfolio, ranked #15.

Partnership Wealth Management first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.53M in Q1 2024. 2,555 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Partnership Wealth Management held 29,948 shares of Bristol-Myers Squibb worth $1.87M as of Q3 2026.
  • Partnership Wealth Management sold 1,408 Bristol-Myers Squibb shares in Q3 2026, an estimated $89K.
  • Bristol-Myers Squibb made up 1.33% of Partnership Wealth Management's portfolio in Q3 2026, its #15 holding.
  • Partnership Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
  • Partnership Wealth Management's Bristol-Myers Squibb position peaked at $2.53M in Q1 2024.
  • 2,555 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Partnership Wealth Management's 13F filing for Q3 2026, filed 5 Oct 2026.